Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Box office analyst Shawn Robbins breaks down how the theater business is faring as two of 2023’s biggest movies are on their way to the Academy Awards.
Burns McKinney, portfolio manager at NFJ Investment Group, discusses how the Fed is balancing recession risks and interest rate cuts, plus whether the tech rally will broaden.
Nick Wolny, CNet editor, tells consumers about BNPL being added to credit reports – and why they may want to be more cautious about using it as an option.
Co-founders of 1953 Tequila, Shivam Mallick Shah and Lindsey Davis Stover, share how they broke into the traditionally male-dominated world of tequila production.
In case you needed yet another incentive to cram all your travel items into a carry-on, Delta Airlines has just boosted the cost of your first checked bag by 17 percent.
